Published 1 month ago

Lumevoq shows sustained efficacy, safety 4 years after one-time LHON treatment

Summary by Ground News

Lumevoq demonstrated sustained efficacy after one injection in patients with Leber hereditary optic neuropathy. The safety profile at 4 years was favorable, with no serious ocular adverse events. The average visual acuity for all eyes treated with the gene therapy improved beyond the +15 letter threshold.

0 Articles

All

Left

Center

Right

Healio

Lumevoq shows sustained efficacy, safety 4 years after one-time LHON treatment

Lumevoq demonstrated sustained efficacy and a positive safety profile at 4 years after a one-time injection of the gene therapy in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.